Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early switch to aflibercept versus continued bevacizumab in diabetic macular edema with suboptimal bevacizumab response
TCTR20190515002Not yet recruiting
- Sponsor
- N/A
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of bevacizumab and aflibercept in diabetic macular edema (DME) (2 arms), sponsored by N/A. Primary endpoint: Visual acuity gain. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
bevacizumabaflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on TCTR20190515002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190515002.